Cancer stem cells (CSCs) are generally dormant or slowly cycling tumor cells that have the ability to reconstitute tumors. They are thought to be involved in tumor resistance to chemo/radiation therapy and tumor relapse and progression. However, neither their existence nor their identity within many cancers has been well defined. Here, we have demonstrated that CD13 is a marker for semiquiescent CSCs in human liver cancer cell lines and clinical samples and that targeting these cells might provide a way to treat this disease. CD13+ cells predominated in the G₀ phase of the cell cycle and typically formed cellular clusters in cancer foci. Following treatment, these cells survived and were enriched along the fibrous capsule where liver cancers usually relapse. Mechanistically, CD13 reduced ROS-induced DNA damage after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse xenograft models, combination of a CD13 inhibitor and the genotoxic chemotherapeutic fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 5-FU inhibited CD90+ proliferating CSCs, some of which produce CD13+ semiquiescent CSCs, while CD13 inhibition suppressed the self-renewing and tumor-initiating ability of dormant CSCs. Therefore, combining a CD13 inhibitor with a ROS-inducing chemo/radiation therapy may improve the treatment of liver cancer.
CD13 is a therapeutic target in human liver cancer stem cells

Naotsugu Haraguchi,1,2 Hideshi Ishii,1,3 Koshi Mimori,3 Fumiaki Tanaka,3 Masahisa Ohkuma,4 Ho Min Kim,1 Hirofumi Akita,1 Daisuke Takuchi,1 Hisanori Hatano,1 Hiroaki Nagano,1 Graham F. Barnard,5 Yuichiro Doki,1 and Masaki Mori1

1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
2Excellent Young Researchers Overseas Visit Program, Japan Society for the Promotion of Science (JSPS), Tokyo, Japan. 3Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. 4Department of Surgery, Jikei University School of Medicine, Tokyo, Japan. 5Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Cancer stem cells (CSCs) are generally dormant or slowly cycling tumor cells that have the ability to reconstitute tumors. They are thought to be involved in tumor resistance to chemo/radiation therapy and tumor relapse and progression. However, neither their existence nor their identity within many cancers has been well defined. Here, we have demonstrated that CD13 is a marker for semiquiescent CSCs in human liver cancer cell lines and clinical samples and that targeting these cells might provide a way to treat this disease. CD13+ cells predominated in the G0 phase of the cell cycle and typically formed cellular clusters in cancer foci. Following treatment, these cells survived and were enriched along the fibrous capsule where liver cancers usually relapse. Mechanistically, CD13 reduced ROS-induced DNA damage after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse xenograft models, combination of a CD13 inhibitor and the genotoxic chemotherapeutic fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 5-FU inhibited CD90+ proliferating CSCs, some of which produce CD13+ semiquiescent CSCs, while CD13 inhibition suppressed the self-renewing and tumor-initiating ability of dormant CSCs. Therefore, combining a CD13 inhibitor with a ROS-inducing chemo/radiation therapy may improve the treatment of liver cancer.

Introduction

Functional and morphologic heterogeneity exists in a tumor with a hierarchy in which tumor growth is driven by a small subset of cancer stem cells (CSCs) (1). Like normal tissue stem cells, which are capable of self-renewal and differentiation, CSCs have the ability to reconstitute tumors (2). In the hematologic cell lineage, stem cells exist in the dormant phase and can be detected as a side population (SP) (3). Generally, CSCs, like somatic tissue stem cells, proliferate slowly, i.e., they are in the dormant or slow-growing phase of the cell cycle. This partially accounts for their therapeutic refractoriness to chemo/radiation therapy, tumor relapse, and presumably metastasis. The CSCs of acute myeloid leukemia (4) and chronic myeloid leukemia (5) also survive in the dormant G0 phase of the cell cycle in a bone marrow niche after chemotherapy. Relapses and metastases of breast cancer often occur after intervals of several decades, suggesting the involvement of a deep dormant phase for CSCs (6). The majority of liver cancers are superimposed on a background of chronic hepatitis and hepatic cirrhosis. Therefore, it may be difficult to distinguish between intrahepatic metastasis through portal or hepatic venules and metachronous multicentric development of liver cancer in a precerescent background. However, there are some cases of liver cancer in which cancer recurs in the liver or metastasizes to the lung and bone several years after radical hepatectomy or liver transplantation. This suggests that some slow-growing cancer cells also exist in liver cancer but these may not be in deep dormancy like breast cancer CSCs. Anticancer reagents in clinical use generally affect division and proliferation of cancer cells. This could result in elimination of proliferating cancer cells but not reduce the survival of CSCs in the dormant or slow-growing phase. Thus, the identification and characterization of dormant or slow-growing CSCs are important for developing novel therapeutic approaches.

In studies of hepatocellular carcinoma (HCC) (7), the fifth most common cancer in the world, the SP fraction (8), CD133+ (9–11), CD44+ (11, 12), CD90+ (12, 13), and epithelial cell adhesion molecules (14) were reported as markers of CSCs or cancer-/tumor-initiating cells. The majority of CSC studies focus on identification of cell markers to enrich cell populations that have high tumor initiation ability in immune-deficient mice. In the field of liver cancer CSCs, there have been few reports describing dormant or slow-growing CSCs that include their cellular characteristics or indicate a way to target these cells based on cytological evidence. In addition, there have been few reports that clearly indicate the interrelationships among these candidate markers.

In a previous study (similar to hematopoietic and leukemic studies), we reported that the SP fraction enriches the CSC-like fraction. Cells of the SP fraction express both hepatocyte and cholangiocyte markers, show high resistance to anti-cancer agents, and high tumorigenicity in NOD/SCID mice (8). Based on our previous data (8) and applying the techniques of hematopoietic stem cell studies (3–5), our aims were as follows: first, to clarify the relationships between reported candidate CSC markers; second, to assess whether dormant CSCs exist in liver cancer; and to concentrate on cell-surface markers, which definitively identify potentially dormant CSCs; third, to clarify the cellular characteristics of potentially dormant CSCs and to identify the mechanisms that protect potentially dormant CSCs from chemo/radiation therapy; finally, to identify target molecules of liver cancer CSCs to initiate novel approaches that could lead to a future radical cure for liver cancer.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2010;120(9):3326–3339. doi:10.1172/JCI42550.
Results

CD13 is a candidate marker closely correlated with SP cells. To identify specific cell-surface markers that correlate with the SP fraction, we utilized our previous data sets of SP and non-SP fraction gene expression profiles obtained using microarray analyses (8). From a list of 268 genes upregulated in the SP cells (with a fold change > 2) (8), we selected 56 genes that potentially encode cell-surface proteins via the UniProtKB database (http://www.uniprot.org/). Working from the list of 56 upregulated genes (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI42550DS1) and an additional 43 markers reported to be closely associated with normal stem cells and CSCs, we tested 47 commercially available antibodies (Supplemental Table 2) to identify surface markers that were enriched in the SP fraction (Figure 1A).

During this screening, we identified 2 candidate markers, CD13 and CD31. The expression analysis of CD13 was 1.64 ± 0.45 in the SP and 0.51 ± 0.03 in the non-SP cell fraction (P < 0.01) (Figure 1B). We focused on CD13 in the current study, since the expression of CD31 was abundant in the G0/M/SP fraction but was not universal in the liver cancer cell lines studied by us (HuH7, PLC/PRF/5, and Hep3B), and the statistical significance was weak (P = 0.076) (Figure 1B and Supplemental Figure 1, A and B). Expression of CD13, CD133, and CD90 in HuH7 (upper panels) and PLC/PRF/5 cells (lower panels). Horizontal and vertical axes denote expression intensity. (D) The SP fraction is recognized as a “beak” appearing beside the G1 phase fraction. The relationship between CD13+ and CD13− cells and the SP fraction was studied using multicolor flow cytometry.

Figure 1

CD13 is a candidate marker of the SP fraction. (A) The strategy used to identify cell-surface markers closely related to the SP fraction. We determined CD13 and CD31 as candidate markers for identifying SP cells. (B) Both CD13 and CD31 expression in HuH7 cells were compared in SP and non-SP cells by semiquantitative RT-PCR. Data represent mean ± SD from independent experiments of fractions differentially sorted by flow cytometry. *P < 0.01; **P = 0.076 versus non-SP fractions. The cut-off lines were determined using isotype controls. (C) Expression of CD13, CD133, and CD90 in HuH7 (upper panels) and PLC/PRF/5 cells (lower panels). Horizontal and vertical axes denote expression intensity. (D) The SP fraction is recognized as a “beak” appearing beside the G1 phase fraction. The relationship between CD13+ and CD13− cells and the SP fraction was studied using multicolor flow cytometry.

Multicolor analysis with Hoechst staining exhibited clear localization of CD13+ cells in the SP fraction of HuH7 and PLC/PRF/5, whereas the CD13+CD133−CD90− fractions were localized to the G1-to-G2 fraction and not the SP fraction (Figure 1D). To confirm the cell-cycle status of the CD13+ cells in PLC/PRF/5, cell-cycle analysis by combined multicolor analysis and 7-amino-actinomy-
cin D (7-AAD) DNA labeling was performed. The CD13<sup>+</sup>CD90<sup>−</sup> population was mainly in the G<sub>0</sub>/G<sub>1</sub> phase, and the CD13<sup>+</sup>CD90<sup>+</sup> population was clearly in the S to G<sub>2</sub>/M phase. The CD13<sup>−</sup>CD90<sup>+</sup> cells were present in all phases of the cell cycle but were more clearly present in the G<sub>2</sub>/M and S phases when compared with the CD13<sup>+</sup>CD90<sup>−</sup> population (Supplemental Figure 1C).

In these studies, we confirmed CD13 as a universal candidate marker that correlates with the liver cancer SP fraction. There were no definitive single markers that showed a stronger correlation to the SP fraction than CD13 and, to a lesser extent, CD31.

CD13 is a marker of tumor-initiating and potentially dormant HCC cells. Given that hematopoietic and leukemic stem cells are in the G<sub>0</sub> phase, identification and characterization of dormant or slow-growing cancer cell populations is very important because of these populations’ relevance to chemo resistance and recurrence. Studies of CD13 expression in HuH7 and PLC/PRF/5 and their relationships with the cell-cycle phase, using the DNA-binding dye Hoechst 33342 and the RNA-binding dye pyronin Y (PY) (3), indicated that most of the CD13<sup>+</sup> fraction exists in the G<sub>1</sub>/G<sub>0</sub> phase and the CD13<sup>−</sup> population was clearly localized in G<sub>0</sub>. The CD13<sup>+</sup> population in HuH7 and the CD90<sup>+</sup> fraction in PLC/PRF/5 were distributed in the G<sub>1</sub>/G<sub>0</sub> and G<sub>2</sub>/M phases, respectively. The relationships between the SP fraction and the G<sub>0</sub> cell-cycle phase were also confirmed, and the SP fraction was clearly localized in the G<sub>0</sub> phase under reserpine-free (ABC transporter blocker) conditions (Figure 2A).

To study the cell fate and dye-retaining capacity of HuH7 CD13<sup>−</sup>CD133<sup>−</sup> cells, the cell-surface membrane was labeled with PKH26GL reagent and cell fate was traced for 238 hours. Equal numbers of cells were seeded for each population. The CD13<sup>−</sup>CD133<sup>−</sup> fraction exhibited very slow growth compared with the CD13<sup>+</sup>CD133<sup>+</sup> fraction, with the doubling time of the CD13<sup>−</sup>CD133<sup>−</sup> fraction estimated...
at approximately 160 hours. Dye-retaining cells could be observed 238 hours after cell seeding only in the CD13+/CD133− fraction (Figure 2B and Supplemental Videos 1–3). The CD13−/CD133− fraction exhibited cell fragmentation and apoptotic changes during cell culture. To confirm CD13 expression in association with cell growth, we performed cell proliferation assays. Data from isolated HuH7 populations showed that CD13−/CD133− cells exhibited slow cell growth compared with CD13+/CD133− cells 72 hours after seeding (Figure 2C). The CD13−/CD133− population also grew slowly but maintained viability for a week, with difficulty, because of apoptosis.

Next, tumor-formation ability of each fraction was studied in HuH7 and PLC/PRF/5 cells. Limiting dilution analysis of HuH7 cells revealed that the CD13−/CD133− fraction formed tumors from 100 cells (2/4), the CD13+/CD133− fraction formed tumors from 1,000 cells (3/4), and the CD13+/CD133+ fraction formed no tumors from 5,000 cells (0/4) in NOD/SCID mice after 4 weeks of observation. In PLC/PRF/5 cells, the CD13−/CD90− fraction formed tumors from 100 cells (2/4), and the CD13−/CD90− fraction formed tumors from 5,000 cells (2/2), whereas the CD13−/CD90− cells formed no tumors from 5,000 cells (0/4) in NOD/SCID mice after 6 weeks of observation (Table 1). To assess the tumor formation ability definitively, formed tumors were digested, and isolated cell fractions of HuH7 and PLC/PRF/5 were also serially transplanted. Tumor formation ability definitively, formed tumors were digested, and isolated cell fractions of HuH7 and PLC/PRF/5 were also serially transplanted to single cells and serially transplanted without isolation of cell-surface markers. BrdU was injected intraperitoneally. After 6 weeks for HuH7, and after 10 weeks for PLC/PRF/5, tumors were enucleated and sections were stained with anti-BrdU and anti-CD13 antibody. In the tumors derived from HuH7 cells, very small numbers of BrdU-containing cells that also expressed CD13 were observed typically in the edge of tumor foci. BrdU-retaining cells were not observed in the tumor center. Tumors derived from PLC/PRF/5 cells grew more slowly than did those derived from HuH7 cells. BrdU-retaining cells could be identified and did express CD13. Interestingly, clusters of CD13+BrdU− cells were observed close to CD13+BrdU+ cells, suggesting that they might be derived from the CD13+BrdU+ cells (Figure 2D).

**Table 1**

Limiting dilution and serial transplantation assay of HuH7 and PLC/PRF/5 cells

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Assay</th>
<th>Marker/cells</th>
<th>1 × 10^2</th>
<th>5 × 10^2</th>
<th>1 × 10^3</th>
<th>5 × 10^3</th>
<th>1 × 10^4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HuH7</td>
<td>Limiting dilution</td>
<td>CD13+/CD133−</td>
<td>2/4</td>
<td>2/4</td>
<td>3/4</td>
<td>3/4</td>
<td>–</td>
</tr>
<tr>
<td>HuH7</td>
<td>Limiting dilution</td>
<td>CD13+/CD133+</td>
<td>0/4</td>
<td>0/4</td>
<td>3/4</td>
<td>4/4</td>
<td>–</td>
</tr>
<tr>
<td>HuH7</td>
<td>Limiting dilution</td>
<td>CD13−/CD133−</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>–</td>
</tr>
<tr>
<td>HuH7</td>
<td>Serial transplantation</td>
<td>CD13+/CD133−</td>
<td>0/4</td>
<td>0/4</td>
<td>3/4</td>
<td>4/4</td>
<td>3/4</td>
</tr>
<tr>
<td>HuH7</td>
<td>Serial transplantation</td>
<td>CD13−/CD133+</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>1/4</td>
</tr>
<tr>
<td>HuH7</td>
<td>Serial transplantation</td>
<td>Control</td>
<td>0/4</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
<td>2/6</td>
</tr>
<tr>
<td>PLC</td>
<td>Limiting dilution</td>
<td>CD13+/CD90−</td>
<td>2/4</td>
<td>2/2</td>
<td>4/4</td>
<td>3/3</td>
<td>–</td>
</tr>
<tr>
<td>PLC</td>
<td>Limiting dilution</td>
<td>CD13−/CD90−</td>
<td>0/4</td>
<td>0/4</td>
<td>3/4</td>
<td>3/4</td>
<td>–</td>
</tr>
<tr>
<td>PLC</td>
<td>Limiting dilution</td>
<td>CD13−/CD90+</td>
<td>0/4</td>
<td>0/4</td>
<td>0/3</td>
<td>0/4</td>
<td>–</td>
</tr>
<tr>
<td>PLC</td>
<td>Serial transplantation</td>
<td>CD13+/CD90−</td>
<td>0/4</td>
<td>2/4</td>
<td>3/4</td>
<td>3/4</td>
<td>–</td>
</tr>
<tr>
<td>PLC</td>
<td>Serial transplantation</td>
<td>CD13−/CD90+</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>0/4</td>
<td>1/4</td>
</tr>
<tr>
<td>PLC</td>
<td>Serial transplantation</td>
<td>Control</td>
<td>0/6</td>
<td>0/6</td>
<td>0/6</td>
<td>1/6</td>
<td>2/6</td>
</tr>
</tbody>
</table>

HCC-CD13+ cells form spheres and produce the CD90− phenotype. Sphere formation is a common characteristic of stem cells. To evaluate CD13 as a candidate CSC marker, the expression of CD13 in spheres derived from HuH7, PLC/PRF/5, and clinical HCC was studied. The expression of CD13 was increased in both HuH7 (2.0% in control vs. 67.0% in spheres; 33.5-fold increase) and PLC/PRF/5 (15.2% in control vs. 83.8% in spheres; 5.51-fold increase) (Figure 3A). There was no significant change in CD13 expression in HuH7. In PLC/PRF/5, expression of CD90 was decreased in the spheres (35.7% in control vs. 2.5% in spheres; 14.28-fold decrease). The expression of CD13 compared with that of CD133 and CD90 appeared to be associated with a more immature stem-like and dormant population. Spheres established from clinical HCC samples localized in the CD13−/CD90−/CD133+ fraction in a manner similar to that observed in PLC/PRF/5 (Figure 3B).

The time-course changes in the expression of CD13 and CD90 in PLC/PRF/5 cells were studied. Isolation and culture of the CD13−/CD90− fraction from the PLC/PRF/5 spheres in serum-containing medium resulted in the production of CD13−/CD90− fraction after 96 hours (Figure 3C). The isolated CD13−/CD90− fraction elicited cell death within a few days and could not be maintained. Interestingly, the isolated CD13−/CD90− fraction rapidly produced the CD13+/CD90+ fraction within 24 hours (Figure 3C). These findings suggest that potentially dormant CD13+ cells produce proliferating CD90− cells and that some parts of the proliferating CD90− cells also produce CD13+ cells. It is important to determine how this CD13+ population (slow-growing potentially dormant) could be maintained in a cancer cell line in vitro. Dormant or slow-growing cell populations may disappear during continuous subculturing. These findings may replicate the rapid change from dormant to active status in cancer stem-like cells, as revealed by their cell-surface markers, or the dormant cells might mimic a certain multipotent condition in cellular differentiation.

CD13+ cells resist chemotherapy, and CD13 inhibition drives cells to apoptosis. The change of cell-surface marker expression before and after doxorubicin (DXR) hydrochloride treatment or 5-fluorouracil (5-FU) was studied in HuH7 and PLC/PRF/5. In HuH7, CD13
expression was increased over 20-fold by DXR or 5-FU treatment compared with control (CD13+CD133+ population in control, 2.0%; by DXR treatment, 40.3%; by 5-FU treatment, 44.3%), although expression of CD133 remained unchanged (87.1% in control vs. 88.0% after DXR treatment, 88.7% after 5-FU treatment). In PLC/PRF/5, after treatment with DXR, the CD13+CD90− fraction was also increased and the CD13−CD90+ fraction was shifted to the CD13 positive (the CD13+CD90− fraction of control was 15.4% and of DXR treatment was 58.2%). After treatment with 5-FU, the remaining cells were more clearly localized in the CD13+CD90− fraction (77.8%) (Figure 4A). The chemo-resistance ability of the CD13+ cells was also confirmed by cell proliferation assay in HuH7. The CD13+CD133− fraction was highly resistant to DXR compared with the CD13−CD133− and CD13−CD133− fractions, indicating consistent changes in the markers following DXR treatment (Supplemental Figure 2A). Although the CD13+CD133− fraction exhibited slow cell growth in the proliferation and cell fate study (Figure 2, B and C), this fraction showed high chemosensitivity.

Next, the effect of CD13 inhibition on cell proliferation in HuH7 was assessed. Cell proliferation was suppressed in a concentration-dependent manner after 72 hours exposure to the CD13-neutralizing antibody. At 10 and 20 μg/ml concentrations of the CD13-neutralizing antibody, cell proliferation was suppressed by approximately 80% at 24 hours and 95% at 72 hours (Figure 4B). The apoptosis assay showed that both the CD13-neutralizing antibody and CD13 inhibitor ubenimex induced apoptosis in both HuH7 and PLC/PRF/5 after 24 hours (Figure 4C). The CD13 antibody (clone WM15) has been shown to be specific to humans and to function as a neutralizing antibody (15). Reportedly, ubenimex (bestatin) specifically blocks CD13, which antagonizes the zinc-binding site of the aminopeptidase N domain (16–19). Ubemimex is used as a therapeutic agent for adult acute nonlymphatic leukemia (20).

We then hypothesized that not only the ABC transporter (21, 22) but also CD13 is involved in cell protection against exposure to anticancer agents. DXR is a well-known ABC-transporter–dependent anticancer drug. We have established a DXR-resistant HuH7 clone in which 90% of cells survive in 0.5 μg/ml of DXR, whereas about 99% of parent HuH7 cells die at that concentration (Supplemental Figure 2, B and C). Inhibition of CD13 indicated approximately 50% suppression of cell proliferation in this clone (Figure 4D), and this finding suggests that CD13 inhibition can potentially suppress cells that may have multidrug-resistance capacities and remain viable after conventional anticancer drug treatments.

CD13 is expressed preferentially in therapy-resistant HCC cells. To identify the expression of CD13 in clinical HCC, HCC samples were digested and hematopoietic Lin−CD45− fractions were further
analyzed by multicolor flow cytometry. In all 12 clinical HCC samples, including 3 cases of non–hepatitis-derived HCC (1 case recurred after transcatheter arterial embolization [TAE]) and 9 cases of hepatitis-derived HCC (4 cases recurred after TAE), no CD133 expression was observed. In all cases, CD13 and CD90 expression was observed in the following 4 subpopulations: CD13$^+$CD90$^+$, CD13$^+$CD90$^-$, CD13$^-$CD90$^+$, and CD13$^-$CD90$^-$. In cases that recurred after TAE, the CD13$^+$CD90$^-$ fraction was more abundant than that in non-TAE cases (48% ± 12% in TAE cases vs. 8% ± 4% in non-TAE cases; 6-fold increase), whereas the CD13$^-$CD90$^+$ fraction was more abundant in non-TAE cases than in TAE cases (40% ± 18% in non-TAE cases vs. 12% ± 5% in TAE cases; 3.3-fold increase) (Figure 5A). In all 12 clinical HCC samples, the expression patterns were very similar to that of PLC/RLF/5, indicating its usefulness as an HCC model. Of course, the percentages of cells just indicate the percentage that survived after mechanical and enzymatic digestion. The majorities of HCC cells retain the cellular functions of liver cells, accumulate fat and glycogen, and produce bilirubin. Also, they are relatively bigger than other kinds of cancer cells and may be more easily damaged by mechanical and enzymatic digestion.

The expression of CD13 was confirmed in fresh frozen surgical specimens. The CD13$^+$ HCC cells typically existed along the fibrous capsule forming cellular clusters after TAE. In non-TAE cases, the CD13$^+$ HCC cells usually formed small cellular clusters inside the cancer foci (Figure 5B). CD13 was expressed on the cell surface in HCC cases. In normal liver samples, CD13 was expressed in the sinusoid with a linear staining pattern and in bile ducts with an intraductal pattern; this was different in the HCC samples. The immunohistochemical findings for the post-TAE cases support clinical experience because HCC recurrence after TAE usually occurs at the fibrous capsule and chemoresistant viable HCC cells exist mainly around the fibrous capsule. Interestingly, some small canalicular structures near the bile ducts expressed CD13 on the cell surface, and these are suggested to be liver stem/progenitor cells, since it has been reported that normal liver stem/progenitor cells express CD13 (23). In our studies, spheres established from the normal liver were predominantly

Figure 4
CD13$^+$ cells resist chemotherapy, and inhibition of CD13 elicits cellular apoptosis. (A) The HuH7 and PLC/PRF/5 cells were treated with 0.1 μg/ml of DXR or 1 μg/ml of 5-FU for 72 hours. The changes in cell-surface markers were compared with controls. The percentages of CD13$^+$CD133$^+$ in HuH7 and CD13$^+$CD90$^-$ populations in PLC/PRF/5 are shown in figure. (B) Effect of CD13 inhibition on cell proliferation. HuH7 cells were treated with various concentrations of anti-human mouse IgG1, CD13-neutralizing antibody. As a negative control, 10 μg/ml of anti-human mouse IgG1 antibody was used. (C) Inhibition of CD13 induces cell apoptosis. Cells were treated with 1–20 μg/ml of CD13-neutralizing antibody or 50–500 μg/ml of ubenimex for 24 hours. Data show each case of 5 μg/ml of CD13-neutralizing antibody and 100 μg/ml of ubenimex treatment. (D) The effect of CD13-neutralizing antibody on DXR-R HuH7. The DXR-R clone was established with continuous treatment in 1 μg/ml of DXR and a selection of viable colonies. In 0.5 μg/ml of DXR, most control HuH7 cells die after 72 hours, whereas over 90% of DXR-R cells survive. The DXR-R HuH7 cells were cultured with 1–20 μg/ml of CD13-neutralizing antibody for 72 hours. Control, treated with 10 μg/ml of anti-human mouse IgG1 antibody.
CD13+, CD90+, and CD133+, with a multidifferentiation potential in both hepatocyte and cholangiocyte lineages (Supplemental Figure 3).

To assess whether the area of the fibrous capsule contributed to the maintenance of semiquiescent CD13+ cells, we stained fresh frozen tissues obtained from HCC parents with a hypoxia marker, carbonic anhydrase 9 (CA9) (24). In hematopoietic stem cells, hypoxia is well known as a hypoxic niche that plays important roles in maintaining stem cells in a dormant phase (25, 26). In the TAE samples, expression of CA9 was localized along the fibrous capsule and coexpressed CD13. In the non-TAE samples, CA9+ cells formed cellular clusters in cancer foci and coexpressed CD13. In normal livers, CA9 expression was limited to the cell surface of bile ducts (Supplemental Figure 4).

CD13 inhibition elicits tumor regression. For preliminary studies, HuH7 cells were transplanted into NOD/SCID mice and treated with 5-FU to determine whether the CD13+ fraction was enriched by treatment with a DNA synthesis inhibitor or not. We used 5-FU, the most common anticancer drug in HCC treatment, to simulate the clinical setting. After 3 days of intraperitoneal administration of 5-FU (30 mg/kg), most Ki67+ active cells were disrupted and remained only at small foci, and tumors were replaced by a majority of CD13+Ki67− cells. Conversely, in ubenimex-treated mice (20 mg/kg, 3 days), most of the CD13+ cells were disrupted and replaced with Ki67+ active cells (Figure 6A).

PLC/PRF/5 was then used for further analyses. The expression of markers in this cell line is similar to that in clinical HCC, and thus, the PLC/PRF/5 cell line is potentially useful as an HCC model. In control mice, CD13 expression was limited to a small fraction and most of the cells expressed CD90. After treatment with 5-FU (30 mg/kg, 5 days of injection and 2 days of withdrawal, 2 courses),
most of the CD90+ cells were disrupted and tumors were replaced by a majority of CD13+ cells. After ubenimex treatment (20 mg/kg every day for 14 days), not only were many CD90+ cells present but CD13+ cells were also identified. Interestingly, in cases in which both ubenimex and 5-FU were administered, the majority of tumor cells were disrupted. We identified atypical, nonspecific CD13 expression in these cases (Figure 6B). Taken together with the findings that CD90+ cells produce CD13+ cells within 24 hours and that almost all of the CD13+ cells were disrupted by ubenimex plus 5-FU treatment, the CD13+ cells that appeared in the ubenimex treatment groups may have been newly produced from residual CD90+ cells. Cytostaining of Ki67 and CD13 revealed that CD13+ cells were negative for the expression of Ki67 (Supplemental Figure 5).

The highly deformed nuclei observed in the ubenimex–plus–5-FU treatment specimens suggested that DNA fragments were present. The DNA fragmentation status was thus assessed by in situ hybridization with terminal deoxynucleotidyl transferase (TdT). There were a few DNA fragments in both the control and 5-FU–treated specimens, whereas there were many more in the ubenimex-treated specimens. Especially in the specimens treated

Figure 6
CD13 inhibition elicits cancer regression in vivo. (A) HuH7-xenografted mice were treated with 5-FU or ubenimex for 3 days. The sections were stained with anti-human CD13 (red), Ki-67 (green), and DAPI (blue). Each right-hand panel shows a high magnification (×20, control and 5-FU; ×40, Ube) of the white dot square on the left (×10, control and 5-FU; ×20, Ube). White arrows: cellular clusters express CD13 but not Ki-67 (upper panels), residual Ki-67+ cancer cells (middle panels), and a residual CD13+ cell (lower panels). (B) PLC/PRF/5-xenografted mice were treated with 5-FU, ubenimex, and ubenimex plus 5-FU for 14 days. The black arrows indicate a small amount of residual cancer. The sections were stained with H&E (×10), anti-human CD13 (red), anti-human CD90 (green), and DAPI (blue) (×20, control, 5-FU, and Ube; ×40, Ube + 5-FU). Nonspecific and fragmented expression of CD13 (white arrow). In situ hybridization for DNA fragmentation (low and high magnification). Black dot-like structures indicate labeled DNA. (C) Tumors of control and ubenimex–plus–5-FU–treated mice. Black arrowheads indicate the tumor margin. (D) The relative tumor volumes (after treatment \(\text{mm}^3\)/before treatment \(\text{mm}^3\) × 100%) of the control, 5-FU, ubenimex, and ubenimex–plus–5-FU–treated mice. Data represent mean ± SD from independent experiments. **P < 0.01. (E) The CD13+ cell–enriched fractions obtained from 5-FU–treated mice were serially transplanted into secondary NOD/SCID mice. The mice were treated with ubenimex (Ube; \(n = 6\)) or received no treatment (control; \(n = 10\)) from the day after transplantation for 7 days. Tumor growth was observed for 3 weeks.
with ubenimex plus 5-FU, there were numerous DNA fragments in residual tumor cells (Figure 6B).

After 14 days of treatment, the tumor volume was significantly decreased in the ubenimex–plus–5-FU groups compared with the control and 5-FU or ubenimex groups (Figure 6, C and D).

Next, we studied the effects of CD13 inhibition as it pertains to the self-renewing ability of cells and repopulation of tumors. The CD13+–enriched fraction obtained from 5-FU–treated mice was serially transplanted into secondary NOD/SCID mice. Starting the day after transplantation, the mice were treated with ubenimex (20 mg/kg) for 7 days. After 3 weeks, no tumor formation was observed in the ubenimex-treated mice (n = 0/6), whereas 60% of the untreated mice grew tumors (n = 6/10) (Figure 6E).

**The CD13+ HCC cells contain lower levels of ROS.** We focused on the ROS scavenger pathway to determine why DNA fragmentation and apoptosis were induced by CD13 inhibition. It has been reported that self-renewing dormant stem cells normally possess low levels of intracellular ROS and that deregulation of ROS levels impairs stem cell functions (27). Intracellular ROS levels were measured by prooxidants using the 2′,7′-dichlorofluorescein diacetate (DCF-DA) stain. Both in HuH7 and PLC/PRF/5, the CD13+ fraction contained lower concentrations of ROS than the CD13-CD90− and CD90+ fractions. After stimulation of oxidative stress by H2O2, a lower concentration of ROS was clearly observed in the CD13+ fraction compared with the CD13− fraction (Figure 7A). Following treatment with the CD13-neutralizing antibody or ubenimex, the ROS concentration was significantly increased in CD13− cells and reached the level of ROS observed in the CD13+ fraction (Figure 7A). In clinical HCC samples, the results were similar to those in PLC/PRF/5, as the CD13+CD90− fraction exhibited lower ROS levels than those in the CD13−CD90− and CD13+CD90− fractions (Figure 7B). The CD13+ fraction also contained another ROS indicator, MitoSOX (a highly selective marker for mitochondrial superoxide), which was markedly lower in the PLC and clinical HCC samples and less in HuH7 (Supplemental Figure 6).

To study the correlation between CD13 and the ROS scavenger pathway, the expression of Gclm was assessed by RT-PCR. Gclm encodes the glutamate-cysteine ligase that catalyses the rate-limiting step of glutathione (GSH), which works as a critical cellular reducing agent and anti-oxidant. Gclm was overexpressed in the CD13+CD90− fraction (P < 0.001) compared with the CD13−CD90−, CD13−CD90+, and CD13+CD90− fractions in PLC/PRF/5 and primary HCC cells (Figure 7C).

It is well known that cell destruction after exposure to cytotoxic chemotherapy and ionizing radiation is partially due to free radicals (28, 29). Given that the present study indicates a low ROS concentration in the CD13+ population, we were interested to see whether chemotherapy agents actually increase ROS level of CD13+ population. To study this, ROS levels of CD13+ populations in HuH7, and CD13− populations in PLC/PRF/5 and clinical HCC samples estimated by semiquantitative RT-PCR. (D) The time-course change of ROS expression in DXR or 5-FU treatment. Cells were treated with 1 μg/ml of DXR and 1 μg/ml of 5-FU continuously. After 3 hours and 48 hours of treatment, ROS levels in each population were measured.
together with the observation that CD13\(^+\) cells remained after treatment with chemotherapy agents (Figure 4A), suggest that ROS levels of all of the cells are temporally upregulated when cells are treated with chemotherapy agents and that this leads to disruption of the CD13\(^+\) population, whereas in the CD13\(^-\) cells, ROS levels are downregulated by the ROS scavenger pathway and the cells survive. In addition, proliferative CD13\(^-\) cells are easily affected by the DNA synthesis inhibition effect of chemotherapy agents.

To assess radiation-induced DNA damage with ROS, purified CD13\(^-\)CD90\(^+\), CD13\(^-\)CD90\(^-\), CD13\(^+\)CD90\(^+\), and CD13\(^+\)CD90\(^-\) PLC/PRF/5 cells were irradiated and subjected to an alkaline comet assay. Although untreated cells did not show significantly different levels of DNA damage, there were fewer DNA strand breaks in CD13\(^+\)CD90\(^-\) cells than in the other 3 fractions \((P < 0.01)\) after ionizing irradiation. The DNA damage in these 3 fractions (but not in the CD13\(^-\)CD90\(^+\) fraction) was significantly inhibited \((P < 0.001)\) by treatment with an antioxidant reagent, tempol (Figure 8A). In HuH7 cells, the CD13\(^+\) fraction also exhibited lower levels of DNA damage compared with the CD13\(^-\) fraction. There was no significant difference between the irradiated and tempol-treated groups for the CD13\(^-\)CD133\(^+\) fraction (Figure 8A). These findings reveal that the enhanced ROS defenses in the CD13\(^+\) fraction contribute to the reduction in DNA damage after genotoxic cancer therapy. To confirm radiation-induced DNA double-strand break status in CD13\(^-\) and CD13\(^+\) populations, time-course change of gamma-H2AX, a marker of double-strand breaks (30), was studied.

In PLC/PRF/5, after 4 Gy of irradiation, gamma-H2AX expression in CD13\(^-\)CD90\(^+\) population increased after 2 hours of irradiation (45.4% ± 5.3%) and then decreased within 6 hours (15.6% ± 4.5%), whereas gamma-H2AX expression in CD13\(^+\)CD90\(^-\) population did not. In HuH7, gamma-H2AX expression increased after 2 hours in both CD13\(^-\)CD133\(^+\) and CD13\(^-\)CD133\(^-\) populations and decreased rapidly in the CD13\(^+\)CD133\(^+\) population (4.4% ± 2.8%) compared with the CD13\(^-\)CD133\(^+\) population (38.4% ± 4.6%) (Figure 8B). After 24 hours of irradiation, the residual cells were localized in the CD13\(^+\) fraction in HuH7 and in the CD13\(^+\)CD90\(^-\) fraction in PLC/PRF/5 (Figure 8C). Although there were some different manners in time-course change of gamma-H2AX in PLC/PRF/5 and HuH7, surviving cells after 24 hours of irradiation were localized in the CD13\(^-\) population, suggesting the radio-resistant characteristics of the CD13\(^-\) population, due to rapid recovery of DNA damage. After 48 hours of irradiation, the residual cells began to proliferate and produced CD13\(^+\)CD133\(^-\) cells in HuH7 and CD13\(^+\)CD90\(^-\) cells in PLC/PRF/5 (Figure 8C). These studies support the time-course studies (Figure 3C) and indicate that CD13\(^+\) cells exist as a core fraction in the cellular hierarchy.

Discussion
To achieve the goal of a radical cure for cancer, recurrence and metastasis caused by residual cancer cells are barriers that need to
be overcome. Recently, the presence of CSCs has attracted attention, and it is thought that these CSCs are intimately involved in cancer recurrence and resistance. In addition, as with leukemia (4, 5), the presence of dormant or slow-growing CSCs is beginning to be recognized in breast cancer (6). However, dormant or slow-growing CSCs have yet to be identified in most solid cancers. In the present study, we identified CD13 as a functional marker that can be used to identify potentially dormant liver CSCs resistant to treatment. Our exploration of SP cells has indicated that CD13+ cancer cells are closely associated with SP cells. Cell-cycle studies indicated that CD13+ cells exist in lower PY lesions. Cell-fate tracing assay with PKH26GL and immunohistochemical analysis of BrdU-retaining cells demonstrated that CD13+ but not CD13− cells exhibited long dye retention and relatively slow proliferation in vitro and in vivo. This population possessed high tumorigenic potential in NOD/SCID mice and also induced chemo resistance. The results of this study are compatible with those of dormancy studies on hematopoietic stem/progenitor (3) and malignant cells (4, 5). CD13, also known as amino peptidase N, is a super family of zinc-binding metalloproteinases that play roles in cellular processes such as mitosis, invasion, cell adhesion, angiogenesis, radiation resistance, and antiapoptosis (31–34). To the best of our knowledge, there have been no reports describing the exclusive expression of CD13 in CSCs of the liver.

The immunohistochemical findings also support the view that CD13+ cells play a role in relapse of liver cancer. The apparent increase in the number of CD13+ cells near the fibrous capsule after TAE is consistent with the fact that clinical HCC relapse after TAE is frequent at the capsule site (7). These findings are compatible with the results of studies in mouse models that revealed that CD13+ cells survived and were amplified after 5-FU treatment. In addition, the preferential accumulation of CD13+ HCC cells at the capsule but not in the central region after TAE therapy suggests the attractive hypothesis that cellular components in the fibrous capsule may function as a protective niche (3).

The suppression of CD13 by the CD13-neutralizing antibody or ubenimex showed an effect even if the cancer cells were resistant to the ABC transporter–dependent agent DXR. This finding suggests that CD13+ cells have some mechanism of resistance to anticancer agents in addition to their slow growth and ABC transporter (21, 35, 36) expressions. It is known that the control of ROS is indispensable for hematopoietic stem cell maintenance. Oxidative stresses inhibit cellular dormancy and self renewal of hematopoietic stem cells (37, 38). In cancer, low ROS levels and radiation resistance in CD44+CD24− breast CSCs has been reported (39). However, an association between ROS and self renewal in CSCs is unknown. In the present study, we demonstrated that CD13+ cells contain low levels of ROS. The CD13+CD133+ and CD90− cells expressed higher levels of the ROS indicators DCF-DA and MitoSOX. RT-PCR of the ROS scavenger pathway gene GCLM and a comet assay also indicated that CD13+ cells protect themselves from oxidant stress via the ROS pathway. Continuous treatment with anticancer agents predominantly elicits high levels of ROS in the CD13+ population. However, in the CD13+ population, it elicits low levels of ROS, and these cells survive and are enriched for after chemotherapy. Mice treated with ubenimex exhibited high DNA fragmentation in xenografted tumors. These findings suggest that the ROS scavenger pathway and CD13 are essential to CSC protection and maintenance in the liver (Figure 9, A and B).

Importantly, tumorigenicity was completely inhibited by treatment with ubenimex in secondary mice xenografted with a CD13+ cell–enriched tumor fraction obtained from 5-FU–treated mice. The suppression of CD13 inhibited self renewal and the tumor-initiation ability of CD13+ cells. It is thought that deregulation of ROS pathway may contribute to disruption of CSCs.

The hierarchy analysis of PLC/PRF/5 cells revealed that a small fraction of CD90− cells produce a small number of CD13+ cells in vitro. This finding indicates that activated CD90− cells should also be involved in targeted cancer therapy. The CD90− cells were resistant and remained in spite of treatment with ubenimex in vivo. The residual CD90− cells cause cancer regrowth and cancer recurrence by producing tumor-initiating CD13+ cells. CD13+ cells have high tumorigenicity and self-renewal ability in vivo. But unfortunately, in the case of liver cancer, it is difficult to target the proliferative CD90− cells by using conventional anticancer drugs because some parts of CD90− cells also express CD13. The expression of CD13 is closely related to the multidrug-resistant SP fraction, and CD13 protects cells from apoptosis via the ROS scavenger pathway. Of course, based on CSC concepts, tumors will disappear when CSCs are disrupted completely. This is because the loss of CSCs leads to the destruction of the hierarchical structure within the tumor. However, it may be difficult to obtain complete pharmacokinetic control, especially in vivo. Actually, in this study, we could not achieve complete disappearance of CD13+ cells and
could not elicit tumor regression by single agent administration of ubenimex. To overcome these problems, we established combination therapy with ubenimex plus 5-FU to efficiently elicit tumor regression. Ubemimex works to disrupt CD13+ cells by its potential effect of upregulating ROS levels and its inhibition of self-renewal of CD13+ cells. 5-FU inhibits proliferative cancer cells, decreases tumor size, and improves survival. It is known that cell destruction after exposure to cytotoxic chemotherapy and ionizing radiation is partially due to free radicals (29, 39), and it is reported that 5-FU induces ROS in hematopoietic stem cells and suppresses the hematopoietic stem cell niche (40). We have also confirmed that 5-FU works to increase the ROS levels of CD13+ populations. By this combination therapy, tumors were drastically regressed compared with single-agent therapy. It is suggested that 5-FU and ubenimex work in a complementary or additive fashion.

Although the majority of the experiments in this study are based on cell lines, the expression, sphere, and ROS analyses support the contention that PLC/PRF/5 cells reflect clinical HCC and may hold promise for preclinical studies. This study also suggests that the future development of liver cancer therapy based on CSC concepts appears promising. We are attempting to establish human HCC xenografted preclinical mouse models from clinical HCC samples to provide necessary confirmation of our contention using in vivo assays.

**Methods**

**Cell culture.** Human liver cancer cells, HuH7 and PLC/PRF/5, obtained from the Cell Resource Center for Biomedical Research, Institute of Develop-

**aging, and Cancer (Tohoku University, Sendai, Japan) were cultured in RPMI 1640 (Invitrogen) medium with 10% FBS (Equate-Bio). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.

**Flow cytometric analysis and cell sorting.** The antibodies used in this study are listed in Supplemental Table 1. Briefly, cells were harvested with trypsin and EDTA. Doublet cells were eliminated using FSC-A/FSC-H and SSC-A/SSC-H. Dead and damaged cells were eliminated with 7-AAD (BD Biosciences — Pharmingen). Isotype controls (BD Biosciences) were used. FCr blocking was performed using an FcR-blocking reagent (Miltenyi-Biotec). FITC-conjugated anti-human CD45 (BD Biosciences — Pharmingen) and FITC-conjugated Lineage Cocktail (Lin1; BD Biosciences — Pharmingen), which contains antibodies against CD3, CD4, CD14, CD16, CD19, CD20, and CD56 and is used to detect lymphocytes, monocytes, eosinophils, and neutrophils, were used for eliminating hematopoietic cells in the clinical sample analysis. For sorting, cells were incubated with 1 µg of each antibody for 30 minutes. Control experiments involved incubation with each antibody for 30 minutes and no apparent increase in the number of dead cells detected by propidium iodide (PI) staining.

**Cell-cycle assay.** To characterize the SP fractions, 1 × 106 cells in 2% FCS/1 mM HEPES buffer/DMEM were preincubated at 37°C for 30 minutes. Cells were then labeled with 10 µg/ml Hoechst 33342 (Molecular Probes) in staining medium at 37°C for 70 minutes. A total of 15 µg/ml reserpine (Sigma-Aldrich) was used for the Hoechst staining procedure. For cell-cycle analysis by PI staining, cells were first stained with Hoechst 33342 at 37°C. After 50 minutes, 1 µg/ml PI was added and the cells were incubated at 37°C for 20 minutes. FACSVantage SE DiVa (BD) and FACS SORP Aria (BD) were used for analysis and cell sorting. The cell cycle was also studied with 10 µg/ml 7-AAD (BD Biosciences — Pharmingen).

**Gene expression study.** Total RNA was prepared using TRIzol reagent (Invitrogen). Reverse transcription was performed with SuperScriptIII (Invitrogen). Quantitative real-time RT-PCR was performed using a LightCycler TaqMan Master kit (Roche Diagnostics). The expression of mRNA copies was normalized against GAPDH mRNA expression. The PCR primers used for amplification were as follows: GCLM, 5'-TGGTGGTATGCACACAGATT-3' and 5'-TTCCACATGACGAGATTCCG-3'; GAPDH, 5'-TGGTATCTGTGGAAGGACTCA-3' and 5'-TGGTATCATTTGGCACAGT-3'.

**Cell proliferation and chemo-resistance assay.** Isolated cells were seeded into 96-well culture plates at 5 × 103 cells/well for cell proliferation assays. After 72 hours, cell viability was determined by an ATP bioluminescence assay (CellTitre-Glo Luminescent Cell Viability Assay; Promega) and the luminescence signal was detected using a luminometer (ARVO MX; PerkinElmer) according to the manufacturer’s protocol. The cells were seeded onto 96-well culture plates at 5 × 103 cells/well. After 24 hours, DXR was added to the culture medium (0.01, 0.05, and 0.1 µg/ml). After 72 hours of exposure to the chemotherapeutic agent, cell viability was determined using a method similar to that used in the cell proliferation assay.

**Cell fate tracing.** Cells were labeled with 20 µM PKH26GL (Sigma-Aldrich) according to the manufacturer’s protocol. Purified populations of cells were isolated and seeded onto 4-chamber polystyrene vessel tissue culture-treated glass slides (Falcon; BD Biosciences) at 5 × 103 cells/well. Cells were cultured in RPMI 1640 (Invitrogen) medium with 20% FBS (Equate-Bio). Cell fate was studied at each 30-minute time point for 238 hours using a time-lapse fluorescence microscope (BZ-9000 Bio Revo; KEYENCE). Data were analyzed using a BZ-II analyzer (KEYENCE). BrdU-retaining cells were identified with fresh frozen samples with the modification of using 5-bromo-2′-deoxyuridine Labeling & Detection Kit 1 (Roche Applied Science) and CD13 rabbit polyclonal antibody (Santa Cruz Biotechnology Inc.). As secondary antibody, anti-rabbit IgG Alexa Fluor 550 (Molecular Probes) was used.

**Sphere assay.** Cells were seeded on ultra-low attachment culture dishes (Corning) in serum-free medium. DMEM/F-12 serum-free medium (Invitrogen) contained 2 mM L-glutamine, 1% sodium pyruvate (Invitrogen), 1% MEM nonessential amino acids (Invitrogen), 1% insulin-transferrin-selenium-X supplement (Invitrogen), 1 µM dexamethasone (Wako), 200 µM L-ascorbic acid 2-phosphate (Sigma-Aldrich), 10 mM nicotinamide (Wako), 100 µg/ml penicillin G, and 100 U/ml streptomycin supplemented with 20 ng/ml epithelial growth factor and 10 ng/ml fibroblast growth factor-2 (PeproTech). Digestion and cell passage were performed every 3 days.

**Differentiation assays from spheres.** Each single sphere established from normal liver cells was seeded into a culture chamber (BD Biosciences). Spheres were cultured in sphere medium containing 10% FBS to induce the differentiation process. Three days after the spheres became attached to the bottom of the chamber and spreading cells appeared, cells were fixed and stained with anti-human CD13 mouse monoclonal antibody (clone WM15, dilution 1:50; Santa Cruz Biotechnology Inc.), FITC–anti-human albumin goat polyclonal antibody (dilution 1:500; Bethyl Laboratories), anti-human Cytokeratin 19 mouse monoclonal antibody (clone RCK108, dilution 1:50; Dako), and anti-human β-2-fetoprotein mouse monoclonal antibody (clone 189502, concentration 5 µg/ml; R&D Systems).

**Immunohistochemistry.** The 4-µm-thick sections were obtained using cryostat and fixed with 4% paraformaldehyde for 15 minutes. After 1 hour of blocking, the sections were incubated overnight at 4°C in a humidified chamber with primary antibodies. For primary antibodies, anti-human CD13 mouse monoclonal antibodies (clone WM15, dilution 1:50; Santa Cruz Biotechnology Inc.), anti-human CA9 rabbit polyclonal antibodies (dilution 1:100; Novus Biologicals), anti-human CD90 rabbit monoclonal antibodies (dilution 1:1000; Epitomics), and anti-human Ki-67 rabbit polyclonal antibodies (dilution 1:1000; Santa Cruz Biotechnology Inc.) were used. For secondary antibodies, goat anti-mouse IgG, Alexa Fluor 546–conjugated, and highly cross-adsorbed (Molecular Probes) as well as goat anti-rabbit IgG, Alexa Fluor 488–conjugated and highly cross-adsorbed (Molecular Probes) antibodies were used. The coverslips were mounted using ProLong Gold and SlowFade Gold Antifade Reagent (Molecular
Probes), and the slides were viewed with a fluorescence microscope (BZ-9000 Biorevo). Data were analyzed using BZ-II (Keyence). The continuous cryostat sections were also stained with modified H&E.

**Tumor cell preparation.** Primary liver cancer samples were obtained from Osaka University with the patients’ informed consent and the approval of the Research Ethics Board of Osaka University. Tumor tissues were cut into approximately 2-mm fragments, further minced with a sterile scalpel, and washed twice with DMEM/10% FBS. They were then placed in DMEM/10% FBS with 2 mg/ml collagenase A (Roche Diagnostics) solution. The mixture was incubated at 37°C with shaking until digestion was complete. Cells were filtered through a 40-μm nylon mesh and washed twice and the cell fragments and debris were then eliminated by Ficoll (GE Healthcare) density gradient centrifugation and stained for flow cytometry.

**Inhibition of CD13.** A total of 5 × 10^5 cells were seeded into 96-well plates in 200 μl of culture medium. After 24 hours, the medium was replaced with fresh culture medium containing 1, 5, 10, and 20 μg/ml mouse monoclonal anti-human CD13 antibodies (clone WM15; Genetex) or 25, 50, 100, 250, and 500 μg/ml umbilinex (Nippon Kayaku). Cell viability was assayed at 24, 48, and 72 hours using Cell Counting Kit-8 (Dojindo) according to the manufacturer’s instructions. Absorbance was measured at 450 nm using a 680 XR microplate reader (Bio-Rad). A total of 10 ng IgG; mouse monoclonal antibody (Genetex) was used as the negative control. DXR-resistant (DXR-R) HuH7 cells were established by continuous treatment with 1 μg/ml DXR and selection of resistant colonies. Cellular apoptosis was measured using PI and Annexin V (BD Pharmingen) with an Apoptosis Detection Kit (BioVision).

**In vivo assay.** The xenografted mouse model was created by injection of 1 × 10^7 HuH7 and PLC/PRF/5 cells into NOD/SCID mice under anesthesia. For injection, the cells were resuspended in a 1:1 mixture of medium and Matrigel (BD Biosciences). The HuH7 cell–xenografted mice were treated with 5-FU (30 mg/kg; intraperitoneal administration) or umbilinex (20 mg/kg; oral administration) for 3 days. On the following day, mice were sacrificed and tumors were excised for the immunohistochemical assay. In the studies of PLC/PRF/5 cell–xenografted mice, mice were treated with 5-FU (30 mg/kg, 5 days of intraperitoneal injection and 2 days of withdrawal, 2 courses; 14 days), umbilinex (20 mg/kg, 14 days of forced oral administration), or umbilinex and 5-FU (combination of 2 courses of 30 mg/kg of 5-FU and 14 days of 20 mg/kg of umbilinex). The tumor size was calculated as follows: tumor volume (mm^3) = a × b × 1/2, where a = long axis and b = short axis. The relative tumor volume was calculated as follows: relative tumor volume (%) = a^3 × b^-1 × 100, where a = tumor volume before treatment (mm^3) and b = tumor volume after 14 days of treatment. The day after 14 days of treatment, mice were sacrificed and tumors were excised for immunohistochemical assay. The relative tumor volume was estimated as follows: relative tumor volume (mm^3) = tumor volume on the day after 14 days of treatment (mm^3)/tumor volume just before the start of treatment (mm^3) × 100 (%). The residual tumors after 14 days of 5-FU treatment were excised and minced into 2-mm squares and subcutaneously transplanted into secondary NOD/SCID mice with Matrigel. The mice were treated with umbilinex (20 mg/kg) from the day after transplantation for 7 days. Tumor growth was observed for 3 weeks. We used 4 or more mice for each model to enable statistical assessment of the results. All animal studies were approved by the Animal Experiments Committee at Osaka University.

**ROS assay.** To study intracellular ROS levels, cells were loaded with 10 μM of DCF-DA at 37°C for 30 minutes. ROS was activated by treatment with 100 μM H_2O_2 at 37°C for 120 minutes. To study the effect of CD13 inhibition on ROS levels, cells were pretreated with 5 μg/ml of the CD13-neutralizing antibody or 25 μg/ml of umbilinex at 37°C for 4 hours and stained with DCF-DA. For mitochondria ROS detection, cells were loaded with 5 μM MitoSOX (Molecular Probes) at 37°C for 20 minutes.

**DNA fragmentation assay.** For the alkaline comet assay, 5,000 isolated cells were irradiated (4 Gy) on ice and suspended in 0.6% of low melting point agarose, spread over the wells of slides, and immersed in alkaline solution for 30 minutes using a kit ( Trevigen). Alkaline electrophoresis was then performed. Slides were stained with silver for visualization. For the comet analysis, cells were treated with 10 mM of tempol ( Sigma-Aldrich) for 15 minutes before irradiation. For in situ hybridization detection of fragmented DNA, 10-μm–thick serial sections obtained from fresh frozen samples were hybridized with TdT using TACS in situ apoptosis detection kit (Trevigen) according to the manufacturer’s protocols.

To identify DNA double-strand breaks, Alexa Fluor 488 Mouse Anti-H2AX (BD Pharmingen) was used according to the manufacturer’s protocols. Briefly, cells were irradiated at 4 Gy. Cells were incubated in culture medium at 37°C in a humidified atmosphere containing 5% CO_2 after irradiation for 0, 2, 4, and 6 hours. After incubation, cells were stained with cell-surface antibodies. Then cells were fixed and permeabilized using Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD), and stained with Alexa Fluor 488 Mouse Anti-H2AX.

**Statistics.** We determined statistical significance by 1-tailed Student’s t test. P < 0.05 was defined as significant.

**Acknowledgments**

We thank T. Shimooka for technical assistance in this study. This work was supported in part by a grant from the Core Research for Evolutional Science and Technology (CREST), a grant-in-aid for Scientific Research on Priority Areas (20012039), a grant-in-aid for Scientific Research (category S) (21229015), and a grant-in-aid for Young Scientists (category B) (21790274) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

Received for publication February 3, 2010, and accepted in revised form June 30, 2010.

Address correspondence to: Masaki Mori, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan. Phone: 81.6.6879.3251; Fax: 81.6.6879.3259; E-mail: mmori@gesurg.med.osaka-u.ac.jp.


